Schizophrénie et consentement à la recherche biomédicale

Fovet, Thomas; Amad, Ali; Thomas, Pierre; Jardri, Renaud

doi:10.1016/j.encep.2014.07.004

Cited by 4 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inclusion criteria of participants in this study are between 16 and 65 years of age, primary diagnosis of schizophrenia, schizoaffective disorder or delusional disorder according to the fifth edition of the DSM-5, and who are found competent to consent to the study in the MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR),31 32 having at least three out of seven points on any one of the seven positive and negative syndrome scale (PANSS) positive symptoms, and those who have taken antipsychotic drugs constantly for 3 months or more and are not planning to change their drugs for the next 3 months. In addition, participants will be required to have internet and computer access and an environment that allows them to take the vCBTp.…”

Section: Methods and Analysismentioning

confidence: 99%

Randomised controlled trial on the effect of video-conference cognitive behavioural therapy for patients with schizophrenia: a study protocol

Katsushima,

Nakamura,

Hanaoka

et al. 2023

BMJ Open

View full text Add to dashboard Cite

IntroductionCognitive behavioural therapy for psychosis (CBTp) has demonstrated effectiveness in reducing positive symptoms, improving depression, enhancing coping skills and increasing awareness of illness. However, compared with cognitive behavioural therapy for depression and anxiety, the spread of CBTp in clinical practice is minimal. The present study designed a randomised controlled trial (RCT) research protocol to evaluate whether real-time remote video-conference CBTp (vCBTp) could facilitate access to psychosocial interventions and effectively improve symptoms compared with usual care (UC) for patients with schizophrenia.Methods and analysisThis exploratory RCT will consist of two parallel groups (vCBTp+UC and UC alone) of 12 participants (n=24) diagnosed with schizophrenia, schizoaffective disorder or paranoid disorder, who remain symptomatic following pharmacotherapy. Seven 50-min weekly vCBTp interventions will be administered to test efficacy. The primary outcome will be the positive and negative syndrome scale score at week 8. The secondary outcome will be the Beck Cognitive Insight Scale to assess insight, the Patient Health Questionnaire-9 to assess depression, the Generalised Anxiety Disorder-7 to assess anxiety, the 5-level EuroQol 5-dimensional questionnaire to assess quality of life and the Impact of Event Scale-Revised to assess subjective distress about a specific stressful life event. We will take all measurements at 0 weeks (baseline) and at 8 weeks (post-intervention), and apply intention-to-treat analysis.Ethics and disseminationWe will conduct this study in the outpatient department of Cognitive Behavioral Therapy Center at Chiba University Hospital. Further, all participants will be informed of the study and will be asked to sign consent forms. We will report according to the Consolidated Standards of Reporting Trials.Trial registration numberUMIN000043396.

show abstract

Section: Methods and Analysismentioning

confidence: 99%